Cell-based therapies of liver diseases: Age-related challenges

Clinical Interventions in Aging

Volumn 10, Issue , 2015, Pages 1909-1924

  Yarygin, Konstantin N ^a   Lupatov, Alexei Y ^a   Vkholodenko, Irina ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Cell aging; Liver cell therapy; Liver engineering; Rejuvenation

Indexed keywords

AGE; AGING; CELL DIFFERENTIATION; CELL EXPANSION; CELL THERAPY; CELL TRANSDIFFERENTIATION; CELL TRANSPLANTATION; DNA METHYLATION; HOLISTIC CARE; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; MESENCHYMAL STEM CELL; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; SKIN FIBROBLAST; TISSUE ENGINEERING; BIOLOGICAL THERAPY; CELL REPROGRAMMING TECHNIQUE; FIBROBLAST; INDUCED PLURIPOTENT STEM CELL; LIVER DISEASES; LIVER REGENERATION; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; PROCEDURES; TELOMERE HOMEOSTASIS;

ACTIVIN; ACTIVIN A; NODAL SIGNALING PROTEIN; WNT PROTEIN;

ACTIVINS; AGE FACTORS; AGING; CELL- AND TISSUE-BASED THERAPY; CELLULAR REPROGRAMMING TECHNIQUES; DNA METHYLATION; FIBROBLASTS; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIVER DISEASES; LIVER REGENERATION; MESENCHYMAL STROMAL CELLS; NODAL SIGNALING LIGANDS; TELOMERE HOMEOSTASIS; TISSUE ENGINEERING; WNT PROTEINS;

EID: 84949812891     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S97926     Document Type: Review

References (164)

1. Belsky DW, Caspi A, Houts R, et al. Quantification of biological aging in young adults. Proc Natl Acad Sci U S A. Epub 2015 Jul 6.
2. Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38–S53.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
4. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44(Suppl 19):96–101.
5. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231.
6. Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3–26.
7. Fukada S, Ma Y, Uezumi A. Adult stem cell and mesenchymal progenitor theories of aging. Front Cell Dev Biol. 2014;2:10.v in the era of induced pluripotency. Cell Stem Cell. 2015;16(6):591–600.
8. Beerman I, Rossi DJ. Epigenetic control of stem cell potential during homeostasis, aging, and disease. Cell Stem Cell. 2015;16(6): 613-625.
9. Nurkovic JS, Volarevic V, Lako M, et al. Aging of stem and progenitor cells: mechanisms, impact on the therapeutic potential and rejuvenation. Rejuvenation Res. Epub 2015 Jun 9
10. Studer L, Vera E, Cornacchia D. Programming and reprogramming cellular age in the era of induced pluripotency. Cell Stem Cell. 2015; 16(6):591-600.
11. Lapasset L, Milhavet O, Prieur A, et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev. 2011;25(21):2248–2253.
12. Miller JD, Ganat YM, Kishinevsky S, et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell. 2013;13(6):691–705.
13. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872.
14. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676.
15. Li H, Collado M, Villasante A, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009;460(7259):1136–1139.
16. Wang B, Miyagoe-Suzuki Y, Yada E, et al. Reprogramming efficiency and quality of induced pluripotent stem cells (iPSCs) generated from muscle-derived fibroblasts of mdx mice at different ages. PLoS Curr. 2011;3:RRN1274.
17. Cheng Z, Ito S, Nishio N, et al. Establishment of induced pluripotent stem cells from aged mice using bone marrow-derived myeloid cells. J Mol Cell Biol. 2011;3(2):91–98.
18. Yagi T, Kosakai A, Ito D, et al. Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS One. 2012;7:e41572.
19. Somers A, Jean JC, Sommer CA, et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells. 2010;28(10):1728–1740.
20. Sharma A, Diecke S, Zhang WY, et al. The role of SIRT6 protein in aging and reprogramming of human induced pluripotent stem cells. J Biol Chem. 2013;288(25):18439–18447.
21. Seki T, Fukuda K. Methods of induced pluripotent stem cells for clinical application. World J Stem Cells. 2015;7(1):116–125.
22. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol. 2008;26(11):1276–1284.
23. Kim JB, Zaehres H, Wu G, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature. 2008;454(7204):646–650.
24. Eminli S, Utikal J, Arnold K, et al. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells. 2008;26(10):2467–2474.
25. Liebau S, Mahaddalkar PU, Kestler HA, et al. Hierarchy in reprogramming capacity in different tissue microenvironments: what we know and what we need to know. Stem Cells Dev. 2013;22(5):695–706.
26. Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell. 2008;133(2):250–264.
27. Maherali N, Ahfeldt T, Rigamonti A, et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell. 2008;3(3):340–345.
28. Abramovich A, Muradian KK, Fraifeld VE. Have we reached the point for in vivo rejuvenation? Rejuvenation Res. 2008;11(2):489–492.
29. Wahlestedt M, Norddahl GL, Sten G, et al. An epigenetic component of hematopoietic stem cell aging amenable to reprogramming into a young state. Blood. 2013;121(21):4257–4264.
30. Rohani L, Johnson AA, Arnold A, Stolzing A. The aging signature: a hallmark of induced pluripotent stem cells? Aging Cell. 2014;13(1):2–7.
31. Marion RM, Blasco MA. Telomere rejuvenation during nuclear reprogramming. Curr Opin Genet Dev. 2010;20(2):190–196.
32. Prigione A, Hossini AM, Lichtner B, et al. Mitochondrial-associated cell death mechanisms are reset to an embryonic-like state in aged donor-derived iPS cells harboring chromosomal aberrations. PLoS One. 2011;6:e27352.
33. Fan J, Robert C, Jang YY, et al. Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining. Mutat Res. 2011; 713(1–2):8–17.
34. Luo LZ, Gopalakrishna-Pillai S, Nay SL, et al. DNA repair in human pluripotent stem cells is distinct from that in nonpluripotent human cells. PLoS One. 2012;7:e30541.
35. Mikkelsen TS, Hanna J, Zhang X, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature. 2008;454(7200):49–55.
36. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009;5(1):111–123.
37. Deng J, Shoemaker R, Xie B, et al. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol. 2009;27(4):353–360.
38. De Carvalho DD, You JS, Jones PA. DNA methylation and cellular reprogramming. Trends Cell Biol. 2010;20(10):609–617.
39. Bar-Nur O, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011;9(1):17–23.
40. Vaskova EA, Stekleneva AE, Medvedev SP, Zakian SM. “Epigenetic memory” phenomenon in induced pluripotent stem cells. Acta Naturae. 2013;5(4):15–21.
41. Clotman F, Lemaigre FP. Control of hepatic differentiation by activin/TGFβ signaling. Cell Cycle. 2006;5(2):168–171.
42. Hewitt NJ, Lechon MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev. 2007;39(1):159–234.
43. Safinia N, Minger SL. Generation of hepatocytes from human embryonic stem cells. Methods Mol Biol. 2009;481:169–180.
44. Terry C, Hughes RD. An optimized method for cryopreservation of human hepatocytes. Methods Mol Biol. 2009;481:25–34.
45. Song Z, Cai J, Liu Y, et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res. 2009;19(11):1233–1242.
46. Si-Tayeb K, Noto FK, Nagaoka M, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology. 2010;51(1):297–305.
47. Sullivan GJ, Hay DC, Park IH, et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology. 2010;51(1):329–335.
48. James D, Levine AJ, Besser D, Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development (Cambridge, England). 2005;132(6):1273–1282.
49. Vallier L, Alexander M, Pedersen RA. Activin/nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci. 2005;118(Pt 19):4495–4509.
50. Burdette JE, Jeruss JS, Kurley SJ, et al. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res. 2005;65(17):7968–7975.
51. Fukuchi Y, Yamato K, Kawamura C, et al. p27KIP1 and GATA-1 are potential downstream molecules in activin A-induced differentiation and apoptosis pathways in CML cells. Oncol Rep. 2006;16(5):1099–1103.
52. Matsuo SE, Leoni SG, Colquhoun A, Kimura ET. Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells. J Endocrinol. 2006;190(1):141–150.
53. Payne C, King J, Hay D. The role of activin/nodal and Wnt signaling in endoderm formation. Vitam Horm. 2011;85:207–216.
54. Fei T, Zhu S, Xia K, et al. Smad2 mediates activin/nodal signaling in mesendoderm differentiation of mouse embryonic stem cells. Cell Res. 2010;20(12):1306–1318.
55. Kubo A, Shinozaki K, Shannon JM, et al. Development of definitive endoderm from embryonic stem cells in culture. Development. 2004;131(7):1651–1662.
56. Guo S, Mao X, He F, et al. Activin A supplement in the hESCs culture enhances the endoderm differentiation efficiency. Cell Biol Int. 2014; 38(7):849–856.
57. Xiao L, Yuan X, Sharkis SJ. Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells. 2006;24(6):1476–1486.
58. Wang Z, Li W, Chen T, et al. Activin A can induce definitive endoderm differentiation from human parthenogenetic embryonic stem cells. Biotechnol Lett. 2015;37(8):1711–1717.
59. Tomizawa M, Shinozaki F, Sugiyama T, et al. Activin A maintains pluripotency markers and proliferative potential of human induced pluripotent stem cells. Exp Ther Med. 2011;2(3):405–408.
60. D’Amour KA, Agulnick AD, Eliazer S, et al. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol. 2005;23(12):1534–1541.
61. Chen YF, Tseng CY, Wang HW, et al. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology. 2012;55(4):1193–1203.
62. Mobarra N, Soleimani M, Kouhkan F, et al. Efficient differentiation of human induced pluripotent stem cell (hiPSC) derived hepatocyte-like cells on hMSCs feeder. Int J Hematol Oncol Stem Cell Res. 2014;8(4):20–29.
63. Sekine K, Takebe T, Suzuki Y, Kamiya A, Nakauchi H, Taniguchi H. Highly efficient generation of definitive endoderm lineage from human induced pluripotent stem cells. Transplant Proc. 2012;44(4):1127–1129.
64. Ao Y, Mich-Basso JD, Lin B, Yang L. High efficient differentiation of functional hepatocytes from porcine induced pluripotent stem cells. PLoS One. 2014;9(6):e100417.
65. Jung J, Zheng M, Goldfarb M, Zaret KS. Initiation of mammalian liver development from endoderm by fibroblast growth factors. Science. 1999;284(5422):1998–2003.
66. Rossi JM, Dunn NR, Hogan BL, Zaret KS. Distinct mesodermal signals, including BMPs from the septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. Genes Dev. 2001;15(15):1998–2009.
67. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995;373(6516):699–702.
68. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010;16(1):37–45.
69. Kamiya A, Kinoshita T, Miyajima A. Oncostatin M and hepatocyte growth factor induce hepatic maturation via distinct signaling pathways. FEBS Lett. 2001;492(1–2):90–94.
70. Michalopoulos GK, Bowen WC, Mule K, Luo J. HGF-, EGF-, and dexamethasone-induced gene expression patterns during formation of tissue in hepatic organoid cultures. Gene Expr. 2003;11(2):55–75.
71. Suzuki A, Iwama A, Miyashita H, et al. Role for growth factors and extracellular matrix in controlling differentiation of prospectively isolated hepatic stem cells. Development. 2003;130(11):2513–2524.
72. Ito Y, Matsui T, Kamiya A, et al. Retroviral gene transfer of signaling molecules into murine fetal hepatocytes defines distinct roles for the STAT3 and ras pathways during hepatic development. Hepatology. 2000;32(6):1370–1376.
73. Matsui T, Kinoshita T, Morikawa Y, et al. K-Ras mediates cytokine-induced formation of E-cadherin-based adherens junctions during liver development. EMBO J. 2002;21(5):1021–1030.
74. Imamura M, Kojima T, Lan M, et al. Oncostatin M induces upregulation of claudin-2 in rodent hepatocytes coinciding with changes in morphology and function of tight junctions. Exp Cell Res. 2007;313(9):1951–1962.
75. Zhang Q, Yang Y, Zhang J, et al. Efficient derivation of functional hepatocytes from mouse induced pluripotent stem cells by a combination of cytokines and sodium butyrate. Chin Med J. 2011;124(22):3786–3793.
76. Nawa K, Nakamura T, Kumatori A, Noda C, Ichihara A. Glucocorticoid-dependent expression of the albumin gene in adult rat hepatocytes. J Biol Chem. 1986;261(36):16883–16888.
77. de Juan C, Benito M, Fabregat I. Regulation of albumin expression in fetal rat hepatocytes cultured under proliferative conditions: role of epidermal growth factor and hormones. J Cell Physiol. 1992;152(1):95–101.
78. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276(5309):71–74.
79. Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science. 1999;284(5417):1168–1170.
80. Alison MR, Poulsom R, Jeffery R, et al. Hepatocytes from non-hepatic adult stem cells. Nature. 2000;406(6793):257.
81. Lagasse E, Connors H, Al-Dhalimy M, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6(11):1229–1234.
82. Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest. 2002;109(10):1291–1302.
83. Kucia M, Reca R, Campbell FR, et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia. 2006;20(5):857–869.
84. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–147.
85. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair – current views. Stem Cells. 2007;25(11):2896–2902.
86. Jameson E. Cellular transplantation for liver diseases. Gastroen Res. 2008;1(1):8–13.
87. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–228.
88. Talens-Visconti R, Bonora A, Jover R, et al. Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. World J Gastroenterol. 2006;12(36):5834–5845.
89. Zemel R, Bachmetov L, Ad-El D, Abraham A, Tur-Kaspa R. Expression of liver-specific markers in naive adipose-derived mesenchymal stem cells. Liver Int. 2009;29(9):1326–1337.
90. Campard D, Lysy PA, Najimi M, Sokal EM. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology. 2008;134(3):833–848.
91. Zhang YN, Lie PC, Wei X. Differentiation of mesenchymal stromal cells derived from umbilical cord Wharton’s jelly into hepatocyte-like cells. Cytotherapy. 2009;11(5):548–558.
92. Hong SH, Gang EJ, Jeong JA, et al. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem Biophys Res Commun. 2005;330(4): 1153–1161.
93. Waclawczyk S, Buchheiser A, Flogel U, Radke TF, Kögler G. In vitro differentiation of unrestricted somatic stem cells into functional hepatic-like cells displaying a hepatocyte-like glucose metabolism. J Cell Physiol. 2010;225(2):545–554.
94. Ishkitiev N, Yaegaki K, Calenic B, et al. Deciduous and permanent dental pulp mesenchymal cells acquire hepatic morphologic and functional features in vitro. J Endod. 2010;36(3):469–474.
95. Kinoshita T, Miyajima A. Cytokine regulation of liver development. Biochim Biophys Acta. 2002;1592(3):303–312.
96. Zhao R, Duncan SA. Embryonic development of the liver. Hepatology. 2005;41(5):956–967.
97. Banas A, Teratani T, Yamamoto Y, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology. 2007;46(1):219–228.
98. Saulnier N, Lattanzi W, Puglisi MA, et al. Mesenchymal stromal cells multipotency and plasticity: induction toward the hepatic lineage. Eur Rev Med Pharmacol Sci. 2009;13(Suppl 1):71–78.
99. Taléns-Visconti R, Bonora A, Jover R, et al. Human mesenchymal stem cells from adipose tissue: differentiation into hepatic lineage. Toxicol In Vitro. 2007;21(2):324–329.
100. Ong SY, Dai H, Leong KW. Hepatic differentiation potential of commercially available human mesenchymal stem cells. Tissue Eng. 2006;12(12):3477–3485.
101. Coradeghini R, Guida C, Scanarotti C, et al. A comparative study of proliferation and hepatic differentiation of human adipose-derived stem cells. Cells Tissues Organs. 2010;191(6):466–477.
102. Snykers S, Vanhaecke T, De Becker A, et al. Chromatin remodeling agent trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow. BMC Dev Biol. 2007;7:24.
103. Yamamoto Y, Banas A, Murata S, et al. A comparative analysis of the transcriptome and signal pathways in hepatic differentiation of human adipose mesenchymal stem cells. FEBS J. 2008;275(6):1260–1273.
104. Saulnier N, Piscaglia AC, Puglisi MA, et al. Molecular mechanisms underlying human adipose tissue-derived stromal cells differentiation into a hepatocyte-like phenotype. Dig Liver Dis. 2010;42(12):895–901.
105. Aurich H, Sgodda M, Kaltwaßer P, et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut. 2009;58(4):570–581.
106. Hwang S, Hong HN, Kim HS, et al. Hepatogenic differentiation of mesenchymal stem cells in a rat model of thioacetamide-induced liver cirrhosis. Cell Biol Int. 2012;36(3):279–288.
107. Yu J, Cao H, Yang J, et al. In vivo hepatic differentiation of mesenchymal stem cells from human umbilical cord blood after transplantation into mice with liver injury. Biochem Biophys Res Commun. 2012;422(4):539–545.
108. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119(Pt 11):2204–2213.
109. Suzdal’tseva YG, Burunova VV, Vakhrushev IV, Yarygin VN, Yarygin KN. Capability of human mesenchymal cells isolated from different sources to differentiation into tissues of mesodermal origin. Bull Exp Biol Med. 2007;143(1):114–121.
110. Crisan M, Yap S, Casteilla L, et al. A perivascular origin of mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301–313.
111. Bernardo ME, Cometa AM, Pagliara D, et al. Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol. 2011;24(1):73–81.
112. Yarygin KN, Suzdal’tseva YG, Burunova VV, et al. Comparative study of adult human skin fibroblasts and umbilical fibroblast-like cells. Bull Exp Biol Med. 2006;141(1):161–166.
113. Lupatov AY, Karalkin PA, Suzdal’tseva YG, et al. Cytofluorometric analysis of phenotypes of human bone marrow and umbilical fibroblast-like cells. Bull Exp Biol Med. 2006;142(4):521–526.
114. Suzdal’tseva YG, Burunova VV, Petrakova NV, Vakhrushev IV, Yarygin KN, Yarygin VN. Comparative analysis of cytophenotypes of cells of mesenchymal lineage isolated from human tissues. Bull Exp Biol Med. 2007;143(1):114–121.
115. Lupatov AY, Vdovin AS, Vakhrushev IV, Poltavtseva RA, Yarygin KN. Comparative analysis of the expression of surface markers on fibroblasts and fibroblast-like cells isolated from different human tissues. Bull Exp Biol Med. 2015;158(4):537–543.
116. Toma JG, McKenzie IA, Bagli D, Miller FD. Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells. 2005;23(6):727–737.
117. Hoogduijn MJ, Gorjup E, Genever PG. Comparative characterization of hair follicle dermal stem cells and bone marrow mesenchymal stem cells. Stem Cells Dev. 2006;15(1):49–60.
118. Kruse C, Bodo E, Petschnik AE, Danner S, Tiede S, Paus R. Towards the development of a pragmatic technique for isolating and differentiating nestin-positive cells from human scalp skin into neuronal and glial cell populations: generating neurons from human skin? Exp Dermatol. 2006;15(10):794–800.
119. Tiede S, Kloepper JE, Bodo E, Tiwari S, Kruse C, Paus R. Hair follicle stem cells: walking the maze. Eur J Cell Biol. 2007;86(7):355–376.
120. Konieva AA, Kholodenko IV, Shragina OA, et al. Functional properties of mesenchymal stem cells labeled with magnetic microparticles in vitro and analysis of their distribution after transplantation. Bull Exp Biol Med. 2010;150(1):131–136.
121. Huang HI, Chen SK, Ling QD, Chien CC, Liu HT, Chan SH. Multilineage differentiation potential of fibroblast-like stromal cells derived from human skin. Tissue Eng Part A. 2010;16(5):1491–1501.
122. Huang HI, Chen SK, Wang RYL, Shen CR, Cheng YC. Human foreskin fibroblast-like stromal cells can differentiate into functional hepatocytic cells. Cell Biol Int. 2013;37(12):1308–1319.
123. Fernandes KJ, McKenzie IA, Mill P. A dermal niche for multipotent adult skin-derived precursor cells. Nat Cell Biol. 2004;6(11):1082–1093.
124. Buranasinsup S, Sila-Asna M, Bunyaratvej N, Bunyaratvej A. In vitro osteogenesis from human skin-derived precursor cells. Dev Growth Differ. 2006;48(4):263–269.
125. Toma JG, Akhavan M, Fernandes KJ, et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol. 2001;3(9):778–784.
126. De Kock J, Vanhaecke T, Biernaskie J, Rogiers V, Snykers S. Characterization and hepatic differentiation of skin-derived precursors from adult foreskin by sequential exposure to hepatogenic cytokines and growth factors reflecting liver development. Toxicol In Vitro. 2009;23(8):1522–1527.
127. Lysy PA, Smets F, Sibille C, et al. Human skin fibroblasts: from mesodermal to hepatocyte-like differentiation. Hepatology. 2007;46(5):1574–1585.
128. Gupta S, Aragona E, Vemuru RP, Bhargava KK, Burk RD, Chowdhury JR. Permanent engraftment and function of hepatocytes delivered to the liver: implications for gene therapy and liver repopulation. Hepatology. 1991;14(1):144–149.
129. Gupta S, Bhargava KK, Novikoff PM. Mechanisms of cell engraftment during liver repopulation with hepatocyte transplantation. Semin Liver Dis. 1999;19(1):15–26.
130. Weber A, Groyer-Picard MT, Franco D, Dagher I. Hepatocyte transplantation in animal models. Liver Transpl. 2009;15(1):7–14.
131. Strom SC, Chowdhury JR, Fox IJ. Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis. 1999;19(1):39–48.
132. Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics. 2003;111(6 pt 1):1262–1267.
133. Ito M, Nagata H, Miyakawa S, Fox IJ. Review of hepatocyte transplantation. J Hepatobiliary Pancreat Surg. 2009;16(2):97–100.
134. Dhawan A, Puppi J, Hughes RD, Mitry RR. Human hepatocyte transplantation: current experience and future challenges. Nat Rev Gastroenterol Hepatol. 2010;7(5):288–298.
135. Lee SY, Kim HJ, Choi D. Cell sources, liver support systems and liver tissue engineering: alternatives to liver transplantation. Int J Stem Cells. 2015;8(1):36–47.
136. Gupta S. Hog heaven on the road to liver cell therapy. Gastroenterology. 2007;132(1):450–453.
137. Nagata H, Nishitai R, Shirota C, et al. Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology. 2007;132(1):321–329.
138. Font-Burgada J, Shalapour S, Ramaswamy S, et al. Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. Cell. 2015;162(4):766–779.
139. Jameson E. Cellular transplantation for liver diseases. Gastroen Res. 2008;1(1):8–13.
140. Liu WH, Song FQ, Ren LN, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med. 2015;19(3):511–520.
141. King A, Barton D, Beard HA, et al. REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. BMJ Open. 2015;5(3):e007700.
142. Ma XR, Tang YL, Xuan M, Chang Z, Wang XY, Liang XH. Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials. Gastroenterol Res Pract. 2015;2015:908275.
143. Zekri AR, Salama H, Medhat E, et al. The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. Stem Cell Res Ther. 2015;6:118.
144. Forbes SJ, Newsome PN. New horizons for stem cell therapy in liver disease. J Hepatol. 2012;56(2):496–499.
145. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011;32(12):3233–3243.
146. Uygun BE, Soto-Gutierrez A, Yagi H, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med. 2010;16(7):814–820.
147. Soto-Gutierrez A, Zhang L, Medberry C, et al. Whole-organ regenerative medicine approach for liver replacement. Tissue Eng Part C Methods. 2011;17(6):677–686.
148. Baptista PM, Siddiqui MM, Lozier G, Rodriguez SR, Atala A, Soker S. The use of whole organ decellularization for the generation of a vascularized liver organoid. Hepatology. 2011;53(2):604–617.
149. Barakat O, Abbasi S, Rodriguez G, et al. Use of decellularized porcine liver for engineering humanized liver organ. J Surg Res. 2012;173(1):e11–e25.
150. Chang R, Emami K, Wu H, Sun W. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model. Biofabrication. 2010;2(4):045004.
151. Ikegami T, Maehara Y. Transplantation: 3D printing of the liver in living donor liver transplantation. Nat Rev Gastroenterol Hepatol. 2013;10(12):697–698.
152. Li CY, Stevens KR, Schwartz RE, Alejandro BS, Huang JH, Bhatia SN. Micropatterned cell–cell interactions enable functional encapsulation of primary hepatocytes in hydrogel microtissues. Tissue Eng Part A. 2014;20(15–16):2200–2212.
153. Blakely AM, Manning KL, Tripathi A, Morgan JR. Bio-pick, place, and perfuse: A new instrument for three-dimensional tissue engineering. Tissue Eng Part C Methods. 2015;21(7):737–746.
154. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008;26(7):739–740.
155. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11(2):147–152.
156. Turner M, Leslie S, Martin NG, et al. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell. 2013;13(4):382–384.
157. Moyse E, Lahousse L, Krantic S. Current research in aging: a report from the 2015 Ageing Summit. Neurodegen Dis Manag. 2015;5(3):187–190.
158. Sanders J, Boudreau R, Newman A. Understanding the aging process using epidemiologic approaches. In: Newman AB, Cauley JA, editors. The Epidemiology of Aging. Dordrecht/Heidelberg/New York: Springer; 2012:187–214.
159. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:R115.
160. Horvath S, Erhart W, Brosch M, et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A. 2014;111(43):15538–15543.
161. Walker RF. On the evolution of anti-aging medicine. Clin Int Aging. 2006;1(3):201–203.
162. Kamao H, Mandai M, Okamoto S, et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports. 2014;2(2):205–218.
163. Riardon S, Cyranoski D. Japan stem-cell trial stirs envy. Nature. 2014;513(7518):287–288.
164. Yamanaka S, Yokoo T. Current bioengineering methods for whole kidney regeneration. Stem Cells Int. 2015;2015:724047.